Autoimmune disorders of the neuromuscular junction

Neurology India

Volumn 56, Issue 3, 2008, Pages 305-313

  Vincent, Angela ^a   Nishino, Ichizo ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Acetylcholine receptor; Autoimmunity; Gravis; Lambert Eaton myasthenic syndrome; Neuromuscular junction; Neuromyotonia; Voltage gated channel

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN G; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ANTHROGRYPOSIS MULTIPLEX CONGENITA; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONGENITAL DISORDER; EATON LAMBERT SYNDROME; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; JOINT CONTRACTURE; LUNG CARCINOMA; METHODOLOGY; MUSCLE CONTRACTION; MUSCLE CRAMP; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOKYMIA; NEUROMUSCULAR SYNAPSE; PATHOPHYSIOLOGY; PRESYNAPTIC NERVE; REVIEW; SMALL CELL CARCINOMA; THYMOMA; THYMUS;

ANIMALS; ANTIBODIES; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; POTASSIUM CHANNELS, VOLTAGE-GATED; RECEPTORS, CHOLINERGIC;

EID: 56049125725     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.43449     Document Type: Review

References (91)

1. Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2001;2:791-805.
2. Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol 2001;64:393-429.
3. Hodgson WC, Wickramaratna JC. In vitro neuromuscular activity of snake venoms. Clin Exp Pharmacol Physiol 2002;29:807-14.
4. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-810.
5. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122-8.
6. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2:797-804.
7. Elmqvist D, Hofmann WW, Kugelberg J, Quastel DM. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol 1964;174:417-34.
8. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors. Science 1973;182:293-5.
9. Chu NS. Contribution of a snake venom toxin to myasthenia gravis: The discovery of alpha-bungarotoxin in Taiwan. J Hist Neurosci 2005;14:138-48.
10. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973;180:871-2.
11. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates and diagnostic value. Neurology 1976;26:1054-9.
12. Vincent A, Whiting PJ, Schluep M, Heidenreich F, Lang B, Roberts A, et al. Antibody heterogeneity and specificity in myasthenia gravis. Ann N Y Acad Sci 1987;505:106-20.
13. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. Neurology 1978;28:266-72.
14. Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: Passive transfer from man to mouse. Science 1975;190:397-9.
15. Yu Wai Man CY, Chinnery PF, Griffiths PG. Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 2005;15:17-23.
16. MacLennan C, Beeson D, Buijs AM, Vincent A, Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 1997;41:423-31.
17. Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 2004;189:333-42.
18. Zhang X, Yang M, Xu J, Lang B, Wang W, Vincent A. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 2007;78:386-90.
19. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
20. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-12.
21. Polizzi A, Huson, S M, Vincent A. Teratogen update: Maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology 2000;62:332-41.
22. Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson SM, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24-5.
23. Jacobson L, Polizzi A, Morriss-Kay G, Vincent A. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. J Clin Invest 1999;103:1031-38.
24. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998;163:89-120.
25. Whiting PJ, Vincent A, Schluep M, Newsom-Davis J. Monoclonal antibodies that distinguish between normal and denervated human acetylcholine receptor. J Neuroimmunol 1986;11:223-35.
26. Vincent A, Willcox N, Hill M, Curnow J, MacLennan C, Beeson D. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol Rev 1998;164:157-68.
27. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, et al. IgG1 antibodies to acetylcholine receptors in "seronegative" MG. Brain;131:1940-52.
28. Weinberg CB, Hall Z W. Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Natl Acad Sci USA 1979;76:504-8.
29. Burges J, Wray DW, Pizzighella S, Hall Z, Vincent A. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 1990;13:407-13.
30. Bufler J, Pitz R, Czep M, Wick M, Franke C. Purified IgG from seropositive and seronegative patients with mysasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 1998;43:458-64.
31. Heinemann S, Bevan S, Kullberg R, Lindstrom J, Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc Natl Acad Sci USA 1977;74:3090-4.
32. Stanley EF, Drachman DB. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science 1978;200:1285-7.
33. Wilson S, Vincent A, Newsom-Davis J. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis: I, Receptor degradation. J Neurol Neurosurg Psychiatry 1983;46:377-82.
34. Wilson S, Vincent A, Newsom-Davis J. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis: II, Receptor synthesis. J Neurol Neurosurg Psychiatry 1983;46:383-7.
35. Guyon T, Wakkach A, Poea S, Mouly V, Klingel-Schmitt I, Levasseur P, et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles: Evidences for a compensatory mechanism triggered by receptor loss. J Clin Invest 1998;102:249-63.
36. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol 1984;16:519-34.
37. Sahashi K, Engel AG, Lambert EH, Howard FM Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980;39:160-72.
38. Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987;505:326-32.
39. Ruff RL, Lennon VA. Endplate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann Neurol 1998;43:370-9.
40. Kaminski HJ, Li Z, Richmonds C, Ruff R.L, Kusner L. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci 2003;998:362-74.
41. Plomp JJ, Van Kempen GT, De Baets MB, Graus YM, Kuks JB, Molenaar PC. Acetylcholine release in myasthenia gravis: Regulation at single end-plate level. Ann Neurol 1995;37:627-36.
42. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Ann Neurol 1987;22:212-22.
43. Mesnard-Rouiller L, Bismuth J, Wakkach A, Poea-Guyon S, Berrih-Aknin S. Thymic myoid cells express high levels of muscle genes. J Neuroimmunol 2004;148:97-105.
44. Scadding GK, Vincent A, Newsom-Davis J, Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: Correlation with thymic histology. Neurology 1981;31:935-43.
45. Vincent A, Newsom-Davis J, Newton P, Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 1983;33:1276-82.
46. Leite MI, Jones M, Ströbel P, Marx A, Gold R, Niks E, et al. Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007;171:893-905.
47. Giraud M, Taubert R, Vandiedonck C, Ke X, Levi-Strauss M, Pagani F, et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007;448:934-7.
48. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001;50:64-72.
49. Strobel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumagi A, et al. Selective loss of regulatory T cells in thymomas. Ann Neurol 2004;56:901-4.
50. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: A distinct disease entity. Lancet 1986;1:116-9.
51. Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994;17:1393-400.
52. Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 2004;5:183-8.
53. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-11.
54. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006;129:1481-92.
55. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8.
56. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: Muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18:519-25.
57. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005;57:444-8.
58. Niks EH, Kuks JB, Roep BO, Haasnoot GW, Verduijn W, Ballieux BE, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66:1772-4.
59. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-4.
60. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-93.
61. Nemoto Y, Kuwabara S, Misawa S, Kawaguchi N, Hattori T, Takamori M, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 2005;76:714-8.
62. Farrugia ME, Kennett RP, Newsom-Davis J, Hilton-Jones D, Vincent A. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve 2006;33:568-70.
63. Spreadbury I, Kishore U, Beeson D, Vincent A. Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation. J Neuroimmunol 2005;162:149-56.
64. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: A review of 50 cases. Brain 1998;111:577-96.
65. Wirtz PW, Willcox N, Roep BO, Lang B, Wintzen AR, Newsom-Davis J, et al. HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma. Ann N Y Acad Sci 2003;998:200-1.
66. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981;2:224-6.
67. Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci 1971;183:183-99.
68. Engel AG. Review of evidence for loss of motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1991;635:246-58.
69. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 1983;80:7636-40.
70. Fukuoka T, Engel AG, Lang B, Newsom-Davis J, Vincent A. Lambert-Eaton myasthenic syndrome: II, Immunoelectron microscopy localization of IgG at the mouse motor end-plate. Ann Neurol 1987;22:200-11.
71. Peers C, Johnston I, Lang B, Wray D. Cross-linking of presynaptic calcium channels: A mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci Lett 1993;153:45-8.
72. Uchitel OD, Protti DA, Sanchez V, Cherksey BD, Sugimori M, Llinas R. P-type voltage-dependent calcium channel mediates presynaptic calcium influx and transmitter release in mammalian synapses. Proc Natl Acad Sci U S A 1992;89:3330-3.
73. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-7.
74. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-74.
75. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002;59:764-6.
76. Pinto A, Gillard S, Moss F, Whyte K, Brust P, Williams M, et al. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 1998;95:8328-33.
77. Giovannini F, Sher E, Webster R, Boot J, Lang B. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br J Pharmacol 2002;136:1135-45.
78. Waterman SA, Lang B, Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol 1997;42:147-156.
79. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome): Report of five cases and literature review. Brain 1993;116:453-69.
80. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002;125:1887-95.
81. Turner MR, Madkhana A, Ebers GC, Clover L, Vincent A, McGavin G, et al. Wasp sting induced autoimmune neuromyotonia. J Neurol Neurosurg Psychiatry 2006:77:704-5.
82. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 1991;338:75-7.
83. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, et al. Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995;38:714-22.
84. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997;41:238-46.
85. Devaux JJ, Kleopa KA, Cooper EC, Scherer SS. KCNQ2 is a nodal K+ channel. J Neurosci 2004;24:1236-44.
86. Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: Subunit specificity correlates with clinical manifestations. Brain 2006;129:1570-84.
87. Sonoda Y, Arimura K, Kurono A, Suehara M, Kameyama M, Minato S, et al. Serum of Isaacs' syndrome suppresses potassium channels in PC-12 cell lines. Muscle Nerve 1996;19:1439-46.
88. Tomimitsu H, Arimura K, Nagado T, Watanabe O, Otsuka R, Kurono A, et al. Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 2004;56:440-4.
89. Arimura K, Sonoda Y, Watanabe O, Nagado T, Kurono A, Tomimitsu H, et al. Isaacs' syndrome as a potassium channelopathy of the nerve. Muscle Nerve 2002;11:S55-8.
90. Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, et al. Morvan's syndrome: Peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001;124:2417-26.
91. Irani SR, Buckley C, Vincent A, Cockerell C, Rudge-P, Johnson MR, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008 in press.